Uncomplicated acute bronchitis

被引:114
作者
Gonzales, R
Sande, MA
机构
[1] Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA
[2] Univ Utah, Dept Med 4C104, Salt Lake City, UT 84132 USA
关键词
D O I
10.7326/0003-4819-133-12-200012190-00014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute bronchitis is an acute cough illness in otherwise healthy adults that usually lasts 1 to 3 weeks. This review describes the pathophysiology of the condition and provides a practical approach to the evaluation and treatment of adults with uncomplicated acute bronchitis. practical points to be made are: 1. Respiratory viruses appear to cause the large majority of cases of uncomplicated acute bronchitis. 2. Pertussis infection is present in up to 10% to 20% of adults with cough illness of more than 2 to 3 weeks' duration. No clinical features distinguish pertussis from nonpertussis infection in adults who were immunized against pertussis as children. 3. Transient bronchial hyperresponsiveness appears to be the predominant mechanism of the bothersome cough of acute bronchitis. 4. Ruling out pneumonia is the primary objective in evaluating adults with acute cough illness in whom comorbid conditions and occult asthma are absent or unlikely. In the absence of abnormalities in vital signs (heart rate > 100 beats/min, respiratory rate > 24 breaths/min, and oral body temperature > 38 degreesC), the likelihood of pneumonia is very low. 5. Randomized, placebo-controlled trials do not support routine antibiotic treatment of uncomplicated acute bronchitis. 6. Randomized, placebo-controlled trials have shown that inhaled albuterol decreases the duration of cough in adults with uncomplicated acute bronchitis. 7. Intervention studies suggest that antibiotic treatment of acute bronchitis can be reduced by using a combination of patient and physician education. Decreased rates of antibiotic treatment are not associated with increased utilization, return visits, or dissatisfaction with care.
引用
收藏
页码:981 / 991
页数:11
相关论文
共 87 条
[31]   Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza [J].
Hayden, FG ;
Atmar, RL ;
Schilling, M ;
Johnson, C ;
Poretz, D ;
Paar, D ;
Huson, L ;
Ward, P ;
Mills, RG .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (18) :1336-1343
[32]   Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections [J].
Hayden, FG ;
Osterhaus, ADME ;
Treanor, JJ ;
Fleming, DM ;
Aoki, FY ;
Nicholson, KG ;
Bohnen, AM ;
Hirst, HM ;
Keene, O ;
Wightman, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) :874-880
[33]   CLINICAL-PREDICTION RULE FOR PULMONARY-INFILTRATES [J].
HECKERLING, PS ;
TAPE, TG ;
WIGTON, RS ;
HISSONG, KK ;
LEIKIN, JB ;
ORNATO, JP ;
CAMERON, JL ;
RACHT, EM .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (09) :664-670
[34]  
Hobbs FDR, 1996, BRIT J GEN PRACT, V46, P395
[35]   Risk factors for 30-day mortality in elderly patients with lower respiratory tract infection - Community-based study [J].
Houston, MS ;
Silverstein, MD ;
Suman, VJ .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (19) :2190-2195
[36]  
HOWIE JGR, 1970, LANCET, V2, P1099
[37]  
HUESTON WJ, 1991, J FAM PRACTICE, V33, P476
[38]  
HUESTON WJ, 1994, J FAM PRACTICE, V39, P437
[39]   Managing cough as a defense mechanism and as a symptom - A consensus panel report of the American College of Chest Physicians [J].
Irwin, RS ;
Boulet, LP ;
Cloutier, MM ;
Fuller, R ;
Gold, PM ;
Hoffstein, V ;
Ing, AJ ;
McCool, FD ;
O'Byrne, P ;
Poe, RH ;
Prakash, UBS ;
Pratter, MR ;
Rubin, BK .
CHEST, 1998, 114 (02) :133S-181S
[40]   ACUTE LOWER RESPIRATORY-TRACT INFECTION ASSOCIATED WITH CHLAMYDIA-PNEUMONIAE IN GERMANY [J].
JANTOS, C ;
ARTELT, P ;
SCHIEFER, HG .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1993, 12 (01) :33-35